Related Experiment Videos
Use of Beta Blockers in Patients with Post-MI Left Ventricular Dysfunction
Alex Adler1, Barry H. Greenberg
1Heart Failure/Transplantation Program, University of California, 200 West Arbor Drive, San Diego, CA 92103, USA. aladler@ucsd.edu
Current Treatment Options in Cardiovascular Medicine
|June 24, 2004
Summary
Beta blockers significantly reduce mortality in heart attack survivors with left ventricular dysfunction. This review covers initiating and maintaining beta blocker therapy for these patients post-myocardial infarction.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta blockers are proven mortality reducers post-myocardial infarction (MI).
- Historically, left ventricular (LV) dysfunction was a contraindication for beta blockers post-MI.
- Newer therapies available today were not present during earlier beta blocker trials.
Purpose of the Study:
- To review the initiation and maintenance of beta blockers in patients with post-MI LV dysfunction.
- To address the uncertainty surrounding beta blocker use in post-MI patients with LV dysfunction.
Main Methods:
- Review of existing literature and clinical trial data.
- Focus on the CAPRICORN study findings.
- Discussion of current clinical practice guidelines.
Main Results:
- The CAPRICORN study demonstrated a significant mortality benefit of carvedilol in post-MI patients with LV dysfunction when added to standard therapy.
- Beta blockers are now routinely used for heart failure with systolic dysfunction.
Conclusions:
- Beta blockers are crucial for managing patients with LV dysfunction after MI.
- Evidence supports the use of carvedilol in this patient population.
- This review provides guidance on beta blocker therapy for post-MI LV dysfunction.